Escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031
This is a first-in-human (FIH), multicenter, double-blind, placebo-controlled, parallel-group, escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031 administered by transforaminal epidural injection to subjects aged 18 to 75 years with neuropathic pain due to LSR.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
18
Kolon Investigative Site : CenExel JBR
Salt Lake City, Utah, United States
The safety and tolerability of KLS-2031
Frequency and nature of AEs, laboratory test results, vital sign measurements, physical and complete neurological examinations, and 12-lead electrocardiograms (ECGs)
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52
Long-term safety and tolerability of KLS-2031
Frequency and nature of AEs, laboratory test results, vital sign measurements, physical and complete neurological examinations, and 12-lead ECGs
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 78, Week 104
Local safety and tolerability (including AEs, clinical laboratory parameters, and physical examination) of administration by transforaminal epidural injectionepidural injection as measured by the occurrence of injection site reactions
The occurrence of injection site reactions
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52
Change from baseline in weekly mean of the average daily pain score
calculated as the average of the subject's last 4 available PI-NRS daily scores in the week before the study visit
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Change from baseline in Galer Neuropathic Pain Scale (Galer NPS)
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Number and percentage of subjects who have ≥30% and ≥50% reduction from baseline in the average daily pain score (PI-NRS)
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Time (number of weeks) to ≥30% and ≥ 50% reduction from baseline in the average daily pain score (PI-NRS)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Number and percentage of subjects who are much improved or very much improved from baseline
based on the Patient Global Impression of Change (PGIC)
Time frame: Week 12, Week 26, Week 52, Week 104
Change from baseline in the modified Modified Roland-Morris Disability Questionnaire (RMDQ) scores (back pain and leg pain)
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Amount of rescue medication used (in terms of dosage/day)
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52
Time to treatment failure
, defined as the day and time a subject starts pain medication other than acetaminophen for the treatment of neuropathic pain
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52
Change from baseline in the Simple Profile of Moods States (POMS) - 2 Short Form total score and domain scores
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Change from baseline in Daily Sleep Interference Scale (DSIS) score
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Change from baseline in the Short Form-36 v2 (SF-36v2) score
Time frame: Week 12, Week 26, Week 52, Week 104
Assessment of suicidality
using the Columbia Suicide Severity Rating Scale (C-SSRS)
Time frame: Week 1, Week 2, Week 4, Week 12, Week 26, Week 52